The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive ...

Biopharmaceutical firms in the U.S. and Europe are turning to China’s biotech sector for new medicines, with licensing ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

RFK Jr. has his sights set on increasing oversight and enforcement against drugmakers that run afoul of advertising laws.

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

Tough times in the industry are forcing changes in investment and governance that should result in a healthier sector, the ...

The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on ...

The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died ...

On an earnings call, CSL CEO Paul McKenzie described weakness in the U.S. market for seasonal flu vaccines as “disappointing” ...

Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff in Maryland.

The two trading partners documented provisions of a deal that would set a 15% tariff on many EU imports, including cars, auto ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could potentially widen access to CAR-T treatment.